Medicare Enrolled
Dr. Joseph McClure, MD
Hematology · Melbourne, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. McClure from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. McClure? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. McClure
Dr. Joseph McClure is a hematology in Melbourne, FL, with 20 years in practice. Based on federal Medicare data, Dr. McClure performed 81,460 Medicare services across 2,672 unique beneficiaries.
Between the years covered by Open Payments, Dr. McClure received a total of $5,692 from 40 pharmaceutical and/or device companies across 250 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. McClure is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ 81,460 Medicare services$ $5,692 industry payments
Medicare Practice Summary
Medicare Utilization ↗81,460
Medicare services
Bottom 47% in FL for hematology
2,672
Unique beneficiaries
$15
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~4,073 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) | 15,750 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 14,200 | $42 | $105 |
| Anti-nausea injection (fosaprepitant) | 11,550 | $0 | $4 |
| Paclitaxel chemotherapy injection | 10,929 | $0 | $2 |
| Denosumab injection (Prolia/Xgeva) | 4,620 | $18 | $45 |
| Oxaliplatin chemotherapy injection | 4,500 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia | 4,280 | $6 | $22 |
| Immune globulin infusion (Gammagard) | 3,060 | $36 | $90 |
| Abatacept infusion (Orencia) | 2,550 | $32 | $101 |
| Dexamethasone injection (steroid) | 1,824 | $0 | $0 |
| Office visit, established patient (30-39 min) | 1,180 | $91 | $255 |
| Anti-nausea injection (Aloxi/palonosetron) | 840 | $1 | $29 |
| Injection, fulvestrant, 25 mg | 660 | $7 | $175 |
| Hospital follow-up visit, high complexity | 573 | $88 | $234 |
| Injection, granisetron hydrochloride, 100 mcg | 490 | $0 | $3 |
| Anti-nausea injection (ondansetron/Zofran) | 372 | $0 | $1 |
| Administration of chemotherapy into vein, 1 hour or less | 367 | $95 | $257 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 360 | $21 | $57 |
| Injection, carboplatin, 50 mg | 308 | $2 | $37 |
| Office visit, established patient (20-29 min) | 306 | $62 | $180 |
| Drug injection, under skin or into muscle | 263 | $10 | $42 |
| Injection, leucovorin calcium, per 50 mg | 232 | $3 | $8 |
| Hospital follow-up visit, moderate complexity | 209 | $61 | $158 |
| Injection of additional new drug or substance into vein | 207 | $12 | $36 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 199 | $47 | $135 |
| Injection, fluorouracil, 500 mg | 182 | $2 | $6 |
| Administration of chemotherapy into vein, each additional hour | 148 | $21 | $56 |
| Initial hospital admission, high complexity | 142 | $134 | $362 |
| Injection, diphenhydramine hcl, up to 50 mg | 133 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 94 | $15 | $40 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 85 | $135 | $999 |
| Administration of additional new drug or substance into vein, 1 hour or less | 84 | $49 | $127 |
| Infusion, normal saline solution , 1000 cc | 82 | $2 | $6 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 81 | $23 | $66 |
| Collection of blood sample from implanted device | 79 | $19 | $52 |
| Injection, zoledronic acid, 1 mg | 75 | $6 | $29 |
| Infusion into a vein for hydration, 31-60 minutes | 62 | $24 | $96 |
| Infusion into a vein for hydration, each additional hour | 58 | $10 | $25 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 48 | $53 | $142 |
| New patient office visit (45-59 min) | 46 | $111 | $336 |
| Initial hospital admission, moderate complexity | 46 | $104 | $265 |
| Administration of additional new drug or substance into vein using push technique | 30 | $42 | $110 |
| Irrigation of implanted venous access drug delivery device | 25 | $16 | $50 |
| Red blood cells, leukocytes reduced, each unit | 25 | $49 | $564 |
| Transfusion of blood or blood products | 22 | $30 | $76 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 21 | $1 | $5 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 18 | $15 | $40 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 17 | $130 | $317 |
| Drawing of blood for a medical problem | 15 | $52 | $190 |
| New patient office visit (30-44 min) | 13 | $70 | $225 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
27.3% high complexity
69.2% medium
3.5% routine
Industry Payment Transparency
Open Payments through 2023 ↗$5,692
Total received (2018-2023)
Avg $949/year across 6 years
Bottom 43% in FL for hematology
40
Companies
250
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,065 (71.4%)
Other
Charitable contributions, space rental, and other categories
$1,465 (25.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$162 (2.8%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2023$289
2022$553
2021$1,069
2020$529
2019$1,378
2018$1,873
Payments by company (2023)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,853
Janssen Biotech, Inc.
$444
PFIZER INC.
$366
Genentech USA, Inc.
$345
E.R. Squibb & Sons, L.L.C.
$319
AstraZeneca Pharmaceuticals LP
$315
AbbVie, Inc.
$188
NOVARTIS PHARMACEUTICALS CORPORATION
$167
Amgen Inc.
$139
Janssen Pharmaceuticals, Inc
$136
Lilly USA, LLC
$126
Daiichi Sankyo Inc.
$114
Chiesi USA, Inc.
$111
Celgene Corporation
$104
Merck Sharp & Dohme Corporation
$103
Novocure Inc.
$73
Pharmacyclics LLC, An AbbVie Company
$70
TerSera Therapeutics LLC
$68
GlaxoSmithKline, LLC.
$62
Takeda Pharmaceuticals U.S.A., Inc.
$60
Incyte Corporation
$55
Astellas Pharma US Inc
$50
Bayer HealthCare Pharmaceuticals Inc.
$49
Seagen Inc.
$47
Helsinn Therapeutics (U.S.), Inc.
$37
TOLMAR Pharmaceuticals, Inc.
$32
Taiho Oncology, Inc.
$31
Puma Biotechnology, Inc.
$28
Gilead Sciences, Inc.
$26
Hologic Sales and Service, LLC
$22
Foundation Medicine, Inc.
$19
GENZYME CORPORATION
$18
Seattle Genetics, Inc.
$17
Janssen Scientific Affairs, LLC
$17
Karyopharm Therapeutics Inc.
$15
Sun Pharmaceutical Industries Inc.
$15
Kite Pharma, Inc.
$13
Eisai Inc.
$13
Medtronic USA, Inc.
$12
Verastem, Inc.
$11
Top 3 companies account for 46.8% of total payments
Associated products mentioned in payments ›
AFINITOR · AKYNZEO · ALIMTA · APTIMA · Abraxane · Alecensa · Avastin · BALVERSA · BLENREP · BOSULIF · CALQUENCE · CHANTIX · CLEVIPREX · CYRAMZA · Copiktra · DARZALEX · ELIGARD · ELIQUIS · EMPLICITI · ERLEADA · Enhertu · Erleada · FOUNDATIONONE · GAZYVA · Herceptin · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INVOKANA · Imbruvica · Inrebic · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kyprolis · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · MEKINIST · NINLARO · Nerlynx · Neulasta · Nplate · Nubeqa · ODOMZO (sonidegib) capsules · OPDIVO · OSTEOCOOL RF ABLATION · Oncology · PADCEV · PEMAZYRE · PIQRAY · PROMACTA · Perjeta · RYBREVANT · Revlimid · SPRYCEL · TAGRISSO · TALZENNA · TASIGNA · TECENTRIQ · TUKYSA · VOTRIENT · Venclexta · XALKORI · XPOVIO · XTANDI · Xofigo · ZOLADEX · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (71%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $7 per 100 Medicare services performed
Geographic Context
Hematologys within 10 mi
10
Per 100K population
1.6
County median income
$75,817
Nearest hospital
HOLMES REGIONAL MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2023 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. McClure is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. McClure experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. McClure performed 15,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. McClure receive payments from pharmaceutical companies?
Yes. Dr. McClure received a total of $5,692 from 40 companies across 250 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. McClure's costs compare to other hematologys in Melbourne?
Dr. McClure's average Medicare payment per service is $15. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. McClure) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologys in Melbourne
Browse hematologys in Melbourne ranked by procedure volume and transparency data.
Highest volume
Top Hematologys in FL
Hematologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologys in FL
Which FL hematologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
PFIZER INC. Payments to Doctors
See all physicians who received payments from PFIZER INC..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology